About MacuSight

Management Team

MacuSight has assembled a management team whose members possess the proven ability to rapidly and successfully build and grow an early-stage ocular disease company. Prior to joining MacuSight, Drs. Weber, Nivaggioli and Reilly, as well as Mr. Kurosaki, played central roles in establishing Oculex Pharmaceuticals as a leading developer of innovative, therapeutic products for the treatment of major, sight-threatening diseases of the eye. The work of this team helped maximize Oculex's corporate value prior to the company's $230 million acquisition by Allergan, Inc.

David A. Weber, Ph.D. - President and Chief Executive Officer

Dr. Weber has a broad research and development background spanning a range of therapeutic drug and device products. Prior to joining MacuSight, Dr. Weber served as acting chief executive officer and executive vice president at Oculex Pharmaceuticals, leading the company until its acquisition by Allergan in November 2003. During his tenure, Dr. Weber led the development of Posurdex^®*, a proprietary, biodegradable, sustained-release ocular implant for the treatment of persistent macular edema. The product was rapidly advanced through Phase 2 clinical trials and produced positive results that attracted the interest of a number of major pharmaceutical and biotechnology companies. The clinical success of Posurdex^® ultimately led to the company's $230 million acquisition by Allergan.

Before his work with Oculex, Dr. Weber served as vice president of research & development at Oral-B Laboratories, where he was responsible for new product development and technology identification for a global consumer and professional oral care business comprised of regulated medical devices and chemical products. In this role, Dr. Weber led the development and launch of innovative new products strengthening market leadership and establishing a solid pipeline of new product opportunities and technology leads. Dr. Weber also held senior management positions in product, regulatory and clinical development while at Oral-B and in Health Care Product Development at The Procter & Gamble Company.

He received his Ph.D. in medical microbiology from Creighton University and his master's and bachelor's degrees in biological sciences from Wichita State University.

Joel Naor, M.D., M.Sc. MBA - Chief Medical Officer

With broad expertise in the clinical development of therapeutics for ocular diseases and conditions, Dr. Naor is responsible for helping to guide the strategic scientific direction of MacuSight, including the company's ongoing advancement of its sirolimus program. Formerly, as a senior medical director at Allergan, Inc., Dr. Naor was a key contributor to the medical and scientific direction of the company's two lead retina programs. In his role as the global project team leader for Allergan's POSURDEX^® program, Dr. Naor oversaw a multifunctional team with responsibilities that spanned clinical development, regulatory, CMC and marketing. Most recently, he served on Allergan's global medical affairs group as a medical director, retina.

Prior to his work with Allergan, Dr. Naor was a director of clinical research at QLT, Inc. where he served as a clinical lead on the global project team for Visudyne^® (verteporfin for injection).

Dr. Naor has authored numerous papers for peer review journals including Archives of Ophthalmology, American Journal of Ophthalmology, Cornea and British Journal of Ophthalmology. He earned his M.D. from the Technion – Israel Institute of Technology and underwent cornea and external disease training at the University of Toronto where he also obtained his M.Sc. in epidemiology. Dr Naor holds a Masters of Business Administration from Simon Fraser University in Vancouver.

Thierry Nivaggioli, Ph.D. - Vice President of Research and Development

Dr. Nivaggioli is responsible for creating and implementing the product development program for sirolimus, MacuSight's lead product candidate. Prior to joining MacuSight, Dr. Nivaggioli held the position of director of research and formulation development at Oculex Pharmaceuticals until its acquisition by Allergan in 2003. Following the acquisition, Dr. Nivaggioli was appointed to the position of senior director, drug delivery formulations by Allergan to help ensure proper transfer of Oculex's technology and intellectual property. Dr. Nivaggioli's tenure at Oculex was highlighted by his development of a new ocular drug delivery extrusion platform that was incorporated into the company's lead product, Posurdex^®. Allergan has since advanced Posurdex^® into Phase 3 clinical trials.

Dr. Nivaggioli has also served as director of development in the Cygnus Drug Delivery Division of Ortho-McNeil Pharmaceutical, and prior to its acquisition by Ortho-McNeil, as Cygnus' manager of research and development.

He received his Ph.D. in polymer science from the University of Toronto, his M.Sc. from the University of Bordeaux in France and his B.Sc. from the University of Paris VI. He completed his post-doctoral studies in the Department of Chemical Engineering at the Massachusetts Institute of Technology.

Philip D. Reilly, J.D., Ph.D. - Vice President and General Counsel

Dr. Reilly is responsible for all legal needs of the company and for assisting in identifying and securing new business opportunities to fuel MacuSight's future growth.

Dr. Reilly has been providing legal support to life science companies since 1995. Prior to joining MacuSight Dr. Reilly was a member of the Intellectual Property practice group of Morrison & Foerster's Palo Alto office. In this role he represented pharmaceutical, materials, nanotechnology, and medical device companies, with his practice focused primarily on the acquisition of intellectual property for such companies and the commercial use of intellectual property through technology-based transactions.

Dr. Reilly is a member of the board of directors of NanoBioNexus, a San Diego based not-for-profit organization dedicated to building awareness and understanding of nanotechnology and fostering business opportunities in the application of nanotechnology in the life sciences. Dr. Reilly holds a J.D. degree with distinction from Stanford Law School, a Ph.D. in chemistry from the University of California, Berkeley and a B.Sc. in chemistry from the University of Sussex, UK. Dr. Reilly performed post-doctoral research at the University of Wisconsin at Madison. He is licensed to practice law in California and is registered to practice before the United States Patent and Trademark Office. He is a member of the State Bar of California, the American Bar Association, and the American Chemical Society.

Shu Kurosaki, CPA - Director, Finance and Administration

Mr. Kurosaki brings a wealth of experience in private company financial management and oversight to MacuSight. Prior to joining the company, Mr. Kurosaki served as director of finance at Oculex Pharmaceuticals where he coordinated and oversaw the company's financial reporting and budgeting responsibilities until Oculex's acquisition by Allergan. Immediately following the acquisition, he assisted in the transition of financial responsibilities and information.

Prior to his work with Oculex, Mr. Kurosaki held the positions of controller at Lumenare Networks and manager of assurance and business advisory services at PricewaterhouseCoopers.

Mr. Kurosaki, a certified public accountant in California, received his bachelor's degree in business administration with a concentration on accounting and marketing from the University of California at Berkeley.

*Posurdex is a registered trademark of Allergan, Inc.